By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.

American Diabetes Association release updated Standards of Care

By Editor
22nd January 2020
Care planning, Clinical guidance

The American Diabetes Association (ADA) has made its annual changes to its Standards of Medical Care in Diabetes.

This year there is a strong recurring message of individualising patient care, including recommendations for treatment of cardiovascular disease, special considerations for older adults with type 1 diabetes, and revised recommendations and additional supporting evidence for use of rapidly changing diabetes technology.

The Standards are developed by the ADA’s multidisciplinary Professional Practice Committee, made up of physicians, diabetes educators, and other expert diabetes healthcare professionals.

The guidelines are based upon the most current evidence-based recommendations for diagnosing and treating adults and children with all forms of diabetes.

Dr John Buse Ph.D., the Verne S. Caviness Distinguished Professor of Medicine, Division Chief of Endocrinology and Metabolism, and Director of the NC Translational and Clinical Sciences (TraCS) Institute, led the writing of the update, which includes:

  • The decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualised HbA1c target;
  • GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and
  • SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

To read the document in full, click here.

Comments (0)

Register an account or login to comment